XOMA Corporation Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Consolidated Financial Statements Details (Tables)

Consolidated Financial Statements Details (Tables)

12 Months Ended

Dec. 31, 2023

Consolidated Financial Statement Details

Schedule of cost, accumulated amortization, impairment charge and net carrying value of intangible assets

The following table summarizes cost, accumulated amortization, impairment charge and net carrying value of the Company’s intangible assets as of December 31, 2023 (in thousands):


			Accumulated		Impairment		Net Carrying
	Cost		Amortization		Charge ⁽¹⁾		Value
As of December 31, 2023
Ebopiprant IP (Note 4)	$	15,247	$	994	$	14,253	$	—
Total intangible assets	$	15,247	$	994	$	14,253	$	—

(1)As of December 31, 2023, the termination of the Organon License agreement indicated that the carrying amount of $14.2 million for the Ebopiprant IP was not recoverable and the Company wrote off the entire finite-lived intangible asset in the consolidated balance sheets and included a $14.2 million impairment charge in the consolidated statements of operations and comprehensive loss.

The following table summarizes cost, accumulated amortization, and net carrying value of intangible assets as of December 31, 2022 (in thousands):


			Accumulated		Net Carrying
	Cost		Amortization		Value
As of December 31, 2022
Ebopiprant IP (Note 4)	$	15,247	$	97	$	15,150
Total intangible assets	$	15,247	$	97	$	15,150

Schedule of accrued and other liabilities

Accrued and other liabilities consisted of the following (in thousands):


	December 31,		December 31,
	2023		2022
Accrued incentive compensation		1,203		562
Accrued legal and accounting fees		791		867
Accrued payroll, severance and retention costs		149		1,449
Other accrued liabilities		625		40
Total	$	2,768	$	2,918